BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 251 filers reported holding BLUEBIRD BIO INC in Q3 2019. The put-call ratio across all filers is 1.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $21 | -4.5% | 7,258 | +4.7% | 0.00% | – |
Q2 2023 | $22 | +10.0% | 6,929 | +3.4% | 0.00% | – |
Q1 2023 | $20 | +5.3% | 6,699 | +135.3% | 0.00% | – |
Q4 2022 | $19 | -99.9% | 2,847 | -21.9% | 0.00% | – |
Q3 2022 | $22,000 | +57.1% | 3,644 | +0.9% | 0.00% | – |
Q2 2022 | $14,000 | -12.5% | 3,613 | +3.9% | 0.00% | – |
Q1 2022 | $16,000 | -82.4% | 3,476 | -62.2% | 0.00% | – |
Q4 2021 | $91,000 | +133.3% | 9,203 | +345.0% | 0.00% | – |
Q3 2021 | $39,000 | -59.8% | 2,068 | -32.8% | 0.00% | – |
Q2 2021 | $97,000 | +9600.0% | 3,076 | +4861.3% | 0.00% | – |
Q1 2021 | $1,000 | -50.0% | 62 | 0.0% | 0.00% | – |
Q4 2020 | $2,000 | -60.0% | 62 | -43.6% | 0.00% | – |
Q3 2020 | $5,000 | -93.9% | 110 | -91.9% | 0.00% | – |
Q2 2020 | $82,000 | +4000.0% | 1,358 | +5804.3% | 0.00% | – |
Q3 2019 | $2,000 | -96.6% | 23 | -96.6% | 0.00% | – |
Q3 2015 | $58,000 | -40.2% | 680 | +17.2% | 0.00% | – |
Q2 2015 | $97,000 | +31.1% | 580 | -5.4% | 0.00% | – |
Q1 2015 | $74,000 | -83.1% | 613 | -87.2% | 0.00% | -100.0% |
Q4 2014 | $437,000 | – | 4,774 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 6,335,528 | $40,104,000 | 4.92% |
qPULA Trading Management LP | 14,344 | $91,000 | 0.80% |
Frazier Life Sciences Management, L.P. | 1,440,757 | $9,120,000 | 0.70% |
Ikarian Capital, LLC | 462,628 | $2,928,000 | 0.58% |
Birchview Capital, LP | 98,000 | $620,000 | 0.44% |
HealthCor Management, L.P. | 455,000 | $2,880,000 | 0.36% |
Financial Advocates Investment Management | 45,071 | $3,538,000 | 0.29% |
PDT Partners, LLC | 262,767 | $1,663,000 | 0.25% |
Monaco Asset Management SAM | 80,000 | $506,000 | 0.19% |
Summit X, LLC | 103,424 | $651,000 | 0.19% |